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Objective. Targeted next generation sequencing (NGS) was evaluated for its ability to identify unanticipated
targetable genomic alterations (GA) for patients with relapsed ovarian epithelial carcinoma (OC).
Methods. DNA sequencing was performed for 3320 exons of 182 cancer-related genes and 37 introns of 14
genes frequently rearranged in cancer on indexed, adaptor ligated, hybridization-captured libraries using
DNA isolated from FFPE sections from 48 histologically veriﬁed relapsed OC specimens. The original primary
tumor was sequenced in 26 (54%) of the cases and recurrent/metastatic tumor site biopsies were sequenced
in 22 (46%) of the cases. Actionability was deﬁned as: GA that predict sensitivity or resistance to approved or
standard therapies or are inclusion or exclusion criteria for speciﬁc experimental therapies in NCI registered
clinical trials.
Results. There were 38 (80%) serous, 5 (10%) endometrioid, 3 (6%) clear cell, 1 mucinous (2%) and 1 (2%)
undifferentiated carcinomas. 141 GA were identiﬁed with an average of 2.9 GA (range 0–8) per tumor, of
which 67were actionable for an average of 1.4 actionable GA per patient (range 0–5). 33/48 (69%) of OC patient
samples harbored at least one actionable GA. Most common GA were TP53 (79%); MYC (25%); BRCA1/2 (23%);
KRAS (16.6%) and NF1 (14.5%). One tumor featured an ERBB2 point mutation. One of 3 (33%) of clear cell tumors
featured cMET ampliﬁcation validated by both FISH and IHC.
Conclusions. NGS assessment of therapy resistant OC identiﬁes an unexpectedly high frequency of GA that
could inﬂuence targeted therapy selection for the disease.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Adenocarcinoma of the ovarian surface epithelium encompasses
90% of all ovarian malignant tumors and is the second most frequentartment of Pathology, Mail Code
: +1 518 262 8092.
nc. Open access under CC BY-NC-ND licensegynecologic malignancy [1–3]. The incidence of ovarian carcinoma
exceeded 22,000 new cases in the United States in 2012 and was re-
sponsible for approximately 14,000 cancer-related deaths [2,3]. De-
spite many attempts to develop methods and tests to detect the
disease at an early stage, 85% of patients diagnosed with epithelial
ovarian cancer present with advanced stage disease [1]. Although
the use of radical surgery and cytotoxic chemotherapy in the last 3
decades has achieved a signiﬁcant improvement in overall survival
from 37% to 46% [3], ovarian cancer remains a major cause of morbid-
ity and mortality for women both in the United States and around
the world. After several decades of clinical trials in the 1990's, the.
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groups formally recommended a combination of platinum and taxane
cytotoxic chemotherapy as the standard of care for epithelial ovarian
cancer [4,5]. However, despite this regimen helping to improve the
survival for this disease, the mortality rate for ovarian cancer patients
with stages III and IV disease continues to be greater than 50% [1]. The
inability to cure and, in many cases slow the progression of ovarian
carcinoma has prompted investigators to search for potential new
targets of systemic therapy that might improve the progression free
and overall survival for the disease. In the following study, whose de-
sign contrasts with The Cancer Genome Atlas study [6] which was
based on primary tumor assessment at the time of diagnosis, this
comprehensive NGS-based test interrogating 182 cancer-related
genes and 14 genes frequently rearranged in cancer was applied to
48 chemo-refractory relapsed/metastatic ovarian epithelial carcino-
mas to identify known and novel drug targets with the aim to person-
alize the therapy for patients with the advanced form of this
life-threatening disease.
Methods
Next generation sequencing (NGS)was performed on hybridization-
captured, adaptor ligation based libraries using DNA extracted from 4
FFPE sections cut at 10 μm from 26 (54%) primary OC and from 22
(46%) recurrent and metastatic tumor sites. The pathologic diagnosis
of each case was conﬁrmed on routine hematoxylin and eosin stained
slides and all samples forwarded for DNA extraction contained a mini-
mum of 20% tumor cells. Based on the submitted pathology reports
that accompanied the tissue samples, of the 22 cases where ametastatic
site was sequenced, 8 (36%) were obtained at the time of ﬁrst surgical
exploration, 10 (45%) were obtained at re-operation and 4 (18%) cases
could not be established as to whether the metastatic site sample was
synchronous with primary tumor surgery or obtained at a second oper-
ation or biopsy procedure. DNA sequencing was performed for 3320
exons of 182 cancer-related genes and 37 introns of 14 genes frequently
rearranged in cancer (1.14 million total bps) on indexed, adaptor ligat-
ed, hybridization-captured (Agilent SureSelect custom kit) and fully
sequenced using 49 bp paired reads on the Illumina HiSeq 2000 to at
an average depth of 877× and evaluated for genomic alterations includ-
ing base substitutions, insertions, deletions, copy number alterations
(ampliﬁcations and homozygous deletions), and select gene fusions/
rearrangements as previously described [7]. The bioinformatics process-
es used in this study included Bayesian algorithms to detect base substi-
tutions, local assembly algorithms to detect short insertions and
deletions, a comparison with process-matched normal control samples
to detect gene copy number alterations and an analysis of chimeric
read pairs to identify gene fusions.
Actionability classiﬁcation
The genomic alterations identiﬁed were further divided into two
main classes of actionability: 1) Genomic alterations that predict sensi-
tivity or resistance to approved or standard therapies and 2) genomic
alterations that are inclusion or exclusion criteria for speciﬁc experi-
mental therapies in NCI registered clinical trials.
Results
Patients and tumors
The 48 ovarian cancer patients included in this study had a mean
age at the time of genomic proﬁling of 55.7 years with a range of 23
to 76 years. There were a range of histologic phenotypes, with 38
(79%) papillary serous carcinomas, 5 (10%) endometrioid carcinomas,
3 (6%) clear cell carcinomas, 1 (2%) mucinous carcinoma and 1 (2%)
undifferentiated carcinoma (Table 1). The majority of these tumorswere high grade lesions, with only 2 (4%) FIGO grade 1 tumors, 6
(12.5%) FIGO grade II tumors and 40 (83%) FIGO grade III tumors.
All of the patients had advanced stage disease at the time of genomic
proﬁling (36 (71%) were stage III and 15 (29%) were stage IV.) In
these 48 relapsed OC cases, the original primary tumor was se-
quenced in 26 (54%) of the cases and recurrent and metastatic
tumor site biopsies were sequenced in 22 (46%) of the cases. Local
site permissions to use clinical samples were used for this study.
A total of 141 genomic alterations were identiﬁed in the 48 OC
with an average of 2.9 alterations per tumor (range 0–8) (Fig. 1).
The most common alterations were TP53 mutation (79% of tumors);
MYC ampliﬁcation (25% of tumors); BRCA1/2 truncation (23%); KRAS
mutation/ampliﬁcation (16.6%) and NF1 mutation truncating alter-
ations (14.5%) (Supplementary Table 1). The TP53 mutations were
identiﬁed in many loci within the TP53 gene and there was no signif-
icant recurrent locus or base substitution seen in this series of cases,
as consistent with previous large-scale sequencing studies. The calcu-
latedMYC gene copy number gains in the 12 cases with ampliﬁcations
varied from 6 to 16 with an average of copy number 9. When the
alterations identiﬁed in the primary tumor specimens (which ulti-
mately relapsed) are compared with the alterations identiﬁed in met-
astatic tumor samples, the ﬁndings were quite similar. Alterations in
the ARID1A (5 patients); PIK3CA (4 patients) and BRAF (2 patients)
genes were uniquely detected in the primary tumors and alterations
in the CCND2 (3 patients); BRCA2 (3 patients); and CCND1; ESR1;
ERBB2; ERBB3; and ERBB4 (1 patient each) were restricted to the met-
astatic tumor samples. A larger follow up series that includes both
primary and relapsed tumors from the same patient is required to de-
termine whether these differences are biologically relevant.
Actionable genomic alterations
Sixty-seven genomic alterations identiﬁed in this series of 48 ovari-
an epithelial carcinomas (1.4 alterations per tumor) were potentially
associated with clinical beneﬁt of targeted therapies (Supplementary
Table 2). Noteworthy genomic alterations potentially impacting the
use of targeted therapy included: 11 (22.9%) tumors with either
BRCA1 or BRCA2 mutations potentially sensitive to PARP inhibitors
and DNA damaging agents. Eight of 8 (100%) of the alterations in
BRCA1 were frame shift truncations including 3 (38%) E23fs*17, 2
(25%) Q1756fs*74, 1 (13%) A17fs*14, 1 (13%) M1775fs*54 and 1 (13%)
Y1522* mutation. Three (6%) of the tumors featured a BRCA2 frame
shift deletion. Of the 8 cases with KRAS genomic alterations potentially
predicting resistance to anti-EGFR targeted therapies and sensitivity to
MEK inhibitors, 6 (75%) were gene ampliﬁcations and 2 (25%) were
point mutations including one G12D and one G13D mutation. Alter-
ations inNF1 that potentially predict responsiveness tomTOR inhibitors
such as everolimus and temsirolimus included 2 nonsense mutations, 2
frame shift deletions, 1(14%) genomic truncation, 1 (14%) splice site
modiﬁcation mutation and 1 (14%) partial gene duplication predicted
to be destructive. There were 4 (8%) tumors with two H1047R and
two E545K PIK3CA mutations, and 1 (2%) AKT3 mutation, also evoking
the potential use of mTOR inhibitors (temsirolimus/everolimus).
There was 1 (2%) tumor with a V842I ERBB2mutation raising potential
for the use of multiple on the market anti-ERBB2 (HER2) targeted
therapies and 1 (2%) tumor with a V104M ERBB3mutation also poten-
tially treatable with anti-ERBB2 targeting agents. One (2%) tumor had
an ATM mutation potentially sensitive to PARP inhibitors. In a single
endometrioid case, an alteration in intron 11 leading to truncation in
PTCH1 was identiﬁed, suggesting potential treatment with a hedgehog
pathway inhibitor such as vismodegib. A total of ﬁve OC harbored the
ampliﬁcations of cell cycle regulatory genes including 1 case each for
CCND1, CCNE1 and CDK4 and 3 cases with ampliﬁcation of CCND2. The
alterations in the cell cycle regulatory genes raise the potential for use
of pazopanib, FGFR inhibitors and CDK4/6 inhibitors. Finally, 2 cases of
ovarian carcinoma (one clear cell and one papillary serous) had c-MET
Table 1
Clinico-pathologic features and summary of genomic alterations in 51 cases of ovarian epithelial carcinoma assessed by tumor type.
Serous carcinoma Endometrioid carcinoma Clear cell carcinoma Mucinous carcinoma Undifferentiated carcinoma
Number of cases 41 5 3 1 1
Mean age 54 57 51 38 67
Low grade cases (grades 1 and 2) 7 1 0 1 0
High grade cases (grade 3) 34 4 3 0 1
Stage III cases 30 1 3 1 1
Stage IV cases 11 4 0 0 0
Mean number of genomic alterations 3.5 2.4 5.7 5 2
Mean number of actionable genomic alterations 0.6 0.8 3.0 2 0
Mean number of available clinical trials 5.1 2.0 9.0 10.0 4
Most frequently altered genes TP53
MYCC
NF1
KRAS
BRCA1
KRAS
TP53
MET AURKA
NOTCH1
FGF1R
BRCA2
MYCC
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including crizotinib.Genomic alterations and pathologic characterizations
Although TP53mutations were seen in 79% of OC, these mutations
were more common in papillary serous carcinomas (83%) than in
non-papillary serous tumors (50%). Only 40% of the endometrioid
and 33% of the clear cell carcinomas featured TP53 mutations. Three
of 5 (60%) of ARID1A mutations also occurred in non-serous tumors.
One of 3 (33%) of CC featured a copy number gain in the MET gene,
which was a high copy number that was also validated by both FISH
and IHC (Fig. 2). The number of genomic alterations and the histologic
grade of the ovarian epithelial carcinoma were positively correlated,
with 8 grades 1 and 2 tumors averaging 2.1 genomic alterations perPrimary
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Fig. 1. Tile plot of genomic alterations in 48 cases of ovarian epithelial malignancy separated
metastatic tumor sample was sequenced.tumor and 40 grade 3 tumors averaging 3.0 alterations per tumor
(p = 0.0003). In contrast, there was no apparent correlation between
the tumor stage and the number of genomic abnormalities in this se-
ries of ovarian carcinomas with the stage III tumors averaging 3.0 al-
terations per tumor and the stage IV tumors averaging 2.8 alterations
per tumor.Discussion
The complexity of genomic alterations found in ovarian epithelial
carcinomas was initially elucidated by traditional cytogenetic and
DNA sequencing techniques, [8]. The large numbers of chromosomal
abnormalities found by cytogenetic and comparative genomic hybrid-
ization studies was difﬁcult to decipher, suggesting the need for a
technology platform such as next generation sequencing that couldMetastasis
23 46 26 14 1 48 2 4 47 41 19 7 45 36 17 10 37 20 13 33 27 28 34 30 31
ozygous deletion  Truncation  Gene fusion/
rearrangement         
into “Primary”when a primary tumor sample was sequenced and “Metastatic”when a
BA
C
Fig. 2.MET ampliﬁcation in clear cell ovarian carcinoma. The panel on the left (A) shows the NGS gene copy number model in the region of chromosome 7. The red circle indicates
an increase in gene copy number to 6 copies at the cMET gene locus measured in a background of DNA estimated to be comprised of 40% tumor cell derived DNA. The panel to the
upper right (B) is the digital image of the ﬂuorescence in situ hybridization analysis of the same tumor using cMET gene copy and chromosome 7 centromere region probes
(Abbott-Vysis, Inc., Downers Grove, IL.) using the Ikoniscope Digital Fluorescence Image Analysis System (Ikonisys, Inc., New Haven, CT.). The cMET copy number detected by
FISH in the same tumor was 6.6 copies/nucleus. The panel to the lower right (C) is the immunohistochemical staining of the same tumor using the Ventana Inform anti-cMET an-
tibody (Ventana Medical Systems, Inc., Tucson, AZ.) showing uniform membranous staining in 100% of the tumor cells (IHC 3+; H score 300).
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high accuracy [9]. Of particular importance was the critical advantage
of next generation sequencing is the capability to simultaneously
characterize all classes of genomic alterations (base substitutions,
short insertions and deletions, fusions/translocations and copy num-
ber alterations including both homozygous deletions and ampliﬁca-
tions) in a single assay. In contrast, the Sanger sequencing methods
initially used are much less sensitive in detecting the former three al-
teration classes [9]. The comprehensive NGS-based genomic proﬁling
assay used in the present study was capable of detecting all four
classes of genomic alterations in routine formalin ﬁxed parafﬁn em-
bedded at high sensitivity and speciﬁcity based on high degree of se-
quencing depth and uniformity averaging greater than 800 fold with
>99% exons covered at least 100 fold, and provided an in depth eval-
uation of such alterations in individual ovarian carcinomas. Given
that fresh or frozen samples were not available for this study, DNA ex-
traction methodologies were optimized for traditional FFPE samples
[7]. The results in the current study conﬁrmed the predominant ﬁnd-
ing of previous studies demonstrating a high frequency of TP53muta-
tions in ovarian carcinoma [10–12], although such mutations are not
known to sensitize cancer cells to current therapies, whether cytotox-
ic or targeted. Speciﬁcally, alterations detected by NGS-based geno-
mic proﬁling in this study correlate extensively with the results of
the Cancer Genome Atlas project which employed focused DNA se-
quencing and, DNA copy number assessment along with assays for
mRNA, microRNA and DNA promoter methylation status assessment
[6]. Using a PCR-based sequencing method, TP53 mutations are
found at a high frequency, especially in high grade serous carcinomas
where they are present in greater than 90% of tumors thus negating
their potential prognostic signiﬁcance for this disease [10]. In thecurrent NGS-based study, TP53 mutations were present in greater
than 85% of high grade serous carcinomas. In the National Cancer Ge-
nome Atlas study, the DNA sequences of exons from coding genes in
316 high grade serous carcinomas were determined and TP53 was
mutated in 96% of the tumors [9]. In contrast, the NF1 mutation rate
in the current series is signiﬁcantly higher than in the previous stud-
ies [9] and COSMIC database. In the current NGS-based study, there
were 7 (14% of cases) tumors with NF1 mutations exclusively found
in tumors that also were positive for TP53 mutation. This association
of NF1 mutation with TP53 mutation in ovarian cancer has been pre-
viously reported [13]. Although this pairing may suggest a possible
deployment of targeted therapy for such NF1 mutant tumors as
in vitro work has demonstrated the sensitivity of NF1 null cells to
mTOR inhibitors, deﬁnitive proof awaits a well-designed clinical
study with appropriate molecular diagnostics gating entry of an ap-
propriately population [14].
Other alterations that suggest a possible deployment of targeted ther-
apy included alterations in the PI3K/mTOR pathway and in members of
the EGFR family. Beyond the previously mentioned NF1 alterations, the
8% of OC with PIK3CA mutation also highlights potential clinical utility
for inhibitors of the mTOR/PI3K pathway. In particular, recent ﬁndings
in breast cancer have suggested a possible synergy for ovarian cancer pa-
tients between PI3K inhibitors and poly-adenylate ribose polymerase
(PARP) inhibitors [15]. There are ongoing clinical studies in both breast
and ovarian carcinoma to assess the efﬁcacy of this combination in pa-
tients. Would mutations in NF1 or PIK3CA potentiate the effects of this
therapeutic combination? Such studies are gated solely on tumor type,
but could beneﬁt from molecular assessments such as in this study.
Although alterations in the ERBB2 (HER2) gene and overexpression
of HER2 protein have driven scientiﬁc interest and launched clinical
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the current study of 48 tumors was noteworthy for the paucity of
ERBB2 alterations, as there were no cases with ERBB2 copy number
gain (≥6 copies) despite copy gain being identiﬁed in many cell
cycle regulatory genes and cMET. The incidence of ERBB2 ampliﬁcation
and/or HER2 protein expression in ovarian epithelial carcinoma has an
extremely wide estimated range of 1.8% to 76% in the published litera-
ture likely reﬂecting the lack of standardization on interpretation of
the slide based assays [16]. The lack of an approvedHER2-targeted ther-
apy for the disease may reﬂect this difﬁculty in identifying the correct
patients for treatment in clinical trials. However, a single (2%) case fea-
tured an ERBB2 mutation, and such mutations have been previously
detected in ovarian carcinomas. The V842I ERBB2 mutation in this
study was identiﬁed in a patient with an advanced clear cell carcinoma
of the ovary within the kinase domain of the HER2 receptor (amino
acids 720−987) (UniProt.org, Jul 2012). In general, such kinase domain
mutations in ERBB2 have been described as activating [17]. The V842I
mutation may therefore be an activating mutation although this has
not been directly demonstrated in functional assays. Finally, over-
expression of HER2 in ovarian cancer is potentially associated with a
poor prognosis, but additional studies to formally demonstrate this
are required [18].
Interestingly, the current study identiﬁed only 1 tumor with a
BRAF mutation and 1 tumor with aBRAF ampliﬁcation (case 40).
BRAF mutation has been linked to favorable prognosis in one study
of ovarian cancer [19], although that mutation was the most common
V600E BRAF mutation and not the G469R mutation found in a high
grade serous carcinoma in the current series. BRAF mutations, pre-
dominantly V600E, have been reported in 10–35% of ovarian cancers
[19], and such mutations are seen more commonly in low grade ovar-
ian tumors rather than in high grade tumors such as the BRAFmutat-
ed case in the current series [20]. The G469R BRAFmutation is located
in the well-characterized G loop domain of Braf and has not been
functionally characterized. Although BRAF inhibitors are effective in
the in vitro context of BRAF-activating mutations, their use can be
paradoxically detrimental by inducing activation of the downstream
MAPK kinase pathway [21,22] and further supporting oncogenic sig-
naling. The BRAF G469R mutation may predict sensitivity to MEK
pathway inhibitors, which have not been approved for ovarian can-
cer, but are under investigation in multiple clinical trials in ovarian
and other solid tumors.
BRCA1/2 mutations are known to confer some sensitivity to DNA
damaging agents, such platinum, or possibly agents that inhibit DNA
repair pathways, i.e. PARP inhibitors. In the present study, 8 (18%)
of tumors had a BRCA1 mutation and 3 (6%) had a BRCA2 mutation.
All 8 (100%) of the ovarian tumors that featured BRCA1 mutations
were serous carcinomas and 7 (88%) had a high histologic grade.
Two of the three tumors with BRCA2 mutations were both high
grade serous carcinomas with stage IV relapses beyond the abdomi-
nal cavity. The National Genome Atlas study also identiﬁed somatic
BRCA1 and BRCA2 mutations as a signiﬁcant feature of high grade se-
rous ovarian carcinoma [9].
One (33%) of the ovarian clear cell carcinomas in this study fea-
tured copy number increase of the MET gene with >6 MET copies
per cell was conﬁrmed by both FISH and immunohistochemical as-
sessment of the MET protein expression level. MET ampliﬁcation has
emerged as a potential biomarker of the clear cell tumor subtype
[23]. Thus, ovarian carcinoma patients with MET ampliﬁcations may
be candidates for referrals to registered clinical trials designed to
test the efﬁcacy of MET inhibitors in this disease. The ALK-targeted
therapeutic used in non-small cell lung cancer, crizotinib, was originally
developed as a MET inhibitor, and correspondingly appears to be also
effective in malignancies with high levelMET ampliﬁcation [24].
A wide variety of other genomic alterations were identiﬁed in
this study that is not currently targetable by either commercially
available therapies or therapies being tested in registered clinicaltrials. Ampliﬁcation of the MYC gene was the second most frequent
genomic alteration identiﬁed at 25% incidence. This frequency is com-
parable to previous studies that used ﬂuorescence in situ hybridiza-
tion to detect MYC copy number [25]. MYC ampliﬁcation has not
been linked with clinico-pathologic features, prognosis or response
to cytotoxic therapy in ovarian carcinomas [25]. The 16.6% incidence
of KRAS genomic alterations is similar to previous reports [26], but
the current study featured 6 tumors with KRAS ampliﬁcation and
only 2 tumors, 1 serous and 1 endometrioid, with KRAS point muta-
tions. Ampliﬁcation of the KRAS gene in ovarian carcinomas has not
been widely reported, and the prognostic and therapeutic implica-
tions are of yet unknown. The absence of a KRAS mutation in the
one mucinous carcinoma included in the current study is of some in-
terest given the recent report that KRAS wild type mucinous ovarian
carcinomas may be sensitive to anti-EGFR antibody-based therapy
with cetuximab [27]. ARID1A alterations were identiﬁed in 5 (10%)
of the ovarian carcinoma cases. ARID1A encodes a protein which is a
member of the SWI/SNF chromatin remodeling complex and is be-
lieved to function as a tumor suppressor [28,29]. ARID1A mutations
have been previously reported in 29% of ovarian tumors, with the
highest prevalence in clear cell carcinomas (up to 57%) [29,30]. In
the current study only 1 (33%) of the clear cell carcinomas featured
an ARID1A mutation. Loss of ARID1A expression in ovarian clear
cell carcinoma has been correlated with advanced tumor stage, and
also with chemoresistance to platinum-based therapy [31]. However,
there are no current therapies that target the inactivation of ARID1A.
In this study, the next generation sequencing of 48 relapsed
ovarian carcinomas generated potential entry into a total of 267
NCI-registered clinical trials of established and experimental targeted
anti-cancer drugs. The number of available clinical trials of targeted
agent available averaged 5.2 per patient.
A number of recent reviews have described the growing interest
in the development of a targeted approach to the treatment of re-
lapsed and refractory ovarian carcinoma [32–37]. The overwhelming
consensus of these studies is that identiﬁcation of therapeutic vulner-
abilities such as genomic alterations are critical to the development of
a clinical targeted approach to treatment of this disease. Furthermore,
a recently published study using the same method as in the current
study conﬁrmed that, for non-small cell lung cancer, the genomic al-
terations identiﬁed in primary tumors are maintained in patient
matched metastatic lesions [38]. The current study demonstrates
that deep sequencing of hundreds of cancer-related gene from DNA
extracted from clinical grade tumor samples of conventional therapy
resistant ovarian carcinomas by NGS uncovers an unexpectedly high
frequency actionable genomic events that may inform targeted treat-
ment decisions.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.ygyno.2013.06.019.
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